PaxVax Inc and Seqirus Inc have entered a marketing and distribution agreement.

Pursuant to the agreement, PaxVax will be responsible to sell and market Agrippal and Fluad, influenza vaccine products of Seqirus, in Switzerland.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The agreement enables PaxVax to expand its vaccines portfolio and Seqirus to market its products in Switzerland.

Qualcomm Incorporated and Boehringer lngelheim Pharmaceuticals have signed a collaboration agreement to jointly improve chronic obstructive pulmonary disease (COPD) care.

Pursuant to the agreement, the two partners will develop a connectivity solution for the latter’s Respimat inhaler to develop respiratory therapies.

The transaction enables the partners to develop new digital technology-based Respimat inhaler.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sichuan Kelun Pharmaceuticals plans to issue bonds due 2021 in a public offering. The company expects to raise gross proceeds of $296.5m through the offering.

"Xiangxue Pharmaceutical Co Ltd has raised gross proceeds of $112.3m through the public offering of first tranche super short-term financing notes."

Xiangxue Pharmaceutical Co Ltd has raised gross proceeds of $112.3m through the public offering of first tranche super short-term financing notes.

China Minsheng Banking Corp has acted as book runner and underwriter to the offering.

Gansu Longshenrongfa Pharmaceutical plans to offer 2.1m common stock shares in an initial public offering.

The company expects to raise gross proceeds of approximately $44.25m from the offering.


Image: Qualcomm is headquartered in San Diego, US. Photo: Courtesy of Coolcaesar.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact